Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 232-142-6 | CAS number: 7789-06-2
Endpoint summary
Administrative data
Description of key information
There are no non-human data on repeated dose effects of strontium chromate. Read-across from sparingly water soluble chromates and from highly water soluble chromates are suggested. Human evidence in several studies with highly water soluble chromates show irritant and corrosive responses in relation to inhalation and dermal exposure.
Key value for chemical safety assessment
Additional information
There are no non-human data on repeated dose effects of strontium chromate. Information on the repeated dose toxicity of other sparingly soluble hexavalent chromium compounds is limited to studies conducted with mainly zinc chromate (one old study of exposure via oral route and showing effects of zinc chromate and a highly water soluble potassium chromate, as well as four studies of exposure via other routes with zinc chromate).
There are, however, several animal studies with highly water soluble chromates via oral or inhalation route. Therefore, in lack of representative data with strontium chromate or other sparingly soluble chromates, it is justified to utilise highly water soluble chromates for read-across purposes. There were no studies available on systemic effects arising from repeated percutaneous exposure to chromium (VI) compounds.
A large number of studies are available relating to repeated exposure of workers to highly water-soluble Cr(VI) (EU RAR 2005). The main effects reported are irritant and corrosive responses in relation to inhalation and dermal exposure. These include inflammation in the lower respiratory tract, and nasal septum perforation in the upper respiratory tract. However, it is not possible to relate these effects to reliable measures of Cr(VI) exposure.
Nasal ulceration and perforation caused by exposure to chromates were recognized already in the 19th century. However, based on the available reports on nasal ulceration and perforation it is not possible to locate threshold doses for these effects (see reports described under title 'human information').
According to Cross et al. (1997) and EU RAR (2005), two reviews also covering the repeated inhalation experiments, it is not possible to identify with confidence a no observed adverse effect level (NOAEL) for Cr(VI) compounds. NOAELs for repeated oral toxicity are suggested in studies with highly water soluble chromates, but these values are received in studies mainly focusing on other effects (e.g., reprotoxicity).
Justification for classification or non-classification
Conclusion: There are no non-human strontium chromate specific data on repeated dose toxicity. Based on the data with mainly highly water soluble chromates, strontium chromate is not suggested to be classified. There is no need for further testing.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
